Lyon, December 20, 2021
– Theranexus, an innovative biopharmaceutical company in the treatment of neurological diseases and a pioneer in the development of drug candidates acting on the interaction between neurons and glial cells, today publishes its financial calendar for the year 2022. The publications will take place after the closing of the Euronext Paris markets, unless otherwise stated. These dates are given as an indication, they are likely to be modified if necessary.
January 13, 2022: Cash flow update at December 31, 2021
April 28, 2022: Annual financial results 2021 and Cash flow update as of March 31, 2022
June 22, 2022: Annual General Meeting
July 12, 2022: Cash flow update as of June 30, 2022
September 27, 2022: Financial results for the 1
er
semester 2022
October 20, 2022: Cash flow update at September 30, 2022
In addition, Theranexus has planned to participate in the following investor events:
January 6-11, 2022: ODDO BHF Forum (digital)
January 26, 2022: Invest Securities BioMed Conference, Paris
April 4-5, 2022: Investor Access, Paris
23-24 June 2022: Spring European Midcap Event, Paris
6-7 October 2022: Investor Access, Paris
|
ABOUT THERANEXUS Founded in 2013, THERANEXUS is a clinical-stage biopharmaceutical company, born out of the CEA, which develops drug candidates for the treatment of diseases of the nervous system. Thanks to its knowledge of neuro-glial interactions, THERANEXUS is a pioneer in the design and combination of approved substances and has a solid and diversified portfolio of active ingredients in the clinical phase. This strategy of combining repositioned drugs based on a solid commercial case and having a real ability to quickly demonstrate their clinical value allows the company to generate different high value-added proprietary drug candidates, significantly reducing the time and costs of development and considerably increase the chances of market access for its drugs. To this end, THERANEXUS is positioned in several indications, including Parkinson’s disease and Batten disease, for which no treatment is currently available on the market. THERANEXUS is listed on the Euronext Growth market in Paris (FR0013286259- ALTHX). |
More information on http://www.theranexus.com
Contacts
THERANEXUS
Thierry lambert
Administrative and financial director
NEWS finance & communication
Claire RIFFAUD
Investor Relations
+33 (0) 1 53 67 36 79
FP2COM
Florence PORTEJOIE
Media Relations
+ 33 (0) 6 07 76 82 83
This publication has the service “? Actusnews SECURITY MASTER”.
– SECURITY MASTER Key:
mGuaZJdmZGablW + bY5WaaGGVb26UmJaVl2PKlJSaaZ + cm25jmJhjmZ2dZnBjmWpu
– To check this key:
https://www.security-master-key.com.
Regulated information:
Inside information:
– Other press releases
Full and original press release in PDF format:
https://www.actusnews.com/news/72458-theranexus_cp_calendrier2022_vdef.pdf
© Copyright Actusnews Wire
Receive free company updates by email by subscribing to www.actusnews.com